In May, the Federal Trade Commission (FTC) required Hikma Pharmaceuticals PLC to divest its 23 percent interest in Unimark Remedies, Ltd. and its US marketing rights to a generic drug under manufacture by Unimark as a condition to allowing Hikma to complete its acquisition of Roxane Laboratories. The FTC was concerned that Hikma’s continued holding of a 23 percent interest in Unimark after consummation of its proposed acquisition of Roxane would create the incentive and ability for Hikma to eliminate future competition between Roxane and Hikma/Unimark in the sale of generic flecainide tablets (a drug used to treat abnormally fast heart rhythms) in the United States.
Lionel Lesur advises domestic and international companies from a broad range of industries, as well as investment funds and top managers, in matters involving corporate and competition/distribution law. Lionel has experience in the negotiation of private mergers and acquisitions, leveraged buyouts (including management packages and long-term incentive plans), and complex commercial contracts. He has in-depth experience with European and French competition law, including international merger control and antitrust proceedings. Lionel also regularly advises clients in relation to distribution strategies and compliance programs. Read Lionel Lesur's full bio.
Where have all the transactions gone? The first quarter has quietly passed by. Just a few weeks ago, looking through the pipeline, one could see almost unimpeded to the other side, relatively empty as the bankers say. But hope exists, as suddenly activity seems to be reemerging. We call it letter of intent flow (more poetically, LOI Flow). The beginnings of real transactions. Concurrently with these beginnings, we launch our inaugural Corporate Deal Source Blog. And perhaps timing is on our side and we are well positioned to ride the next wave of deal activity from its very beginning.
We set out here to provide commentary, not intended for other lawyers, but for our clients and those we hope will find benefit from becoming our clients. Our goal is to dialogue as much as one can in the blogosphere and that our followers will help drive our content through comment and suggestion. The Corporate Deal Source Blog aims to be a professional, yet light-hearted source of pertinent information. Some posts will be pithy updates of the LOI Flow, announcements and important releases; others will be more comprehensive analysis of meaningful changes in law, pitfalls in transacting globally or recent trends in private equity buyouts. We will also cover issues affecting family office direct investing, corporate finance, real estate transactions and other topics of interest. But all well tied with a common theme: deal-making and the people who make them.
With that, we invite you to follow Corporate Deal Source—a must for any true deal-maker. We promise to excite as much as any band of lawyers possibly can.